The present prospective, multicenter phase II study was conducted to evaluate the feasibility of shorter, 15-minute panitumumab infusions in patients with KRAS wild-type oxaliplatin-or irinotecan-refractory metastatic colorectal cancer. The findings indicate that 15-minute panitumumab infusions has efficacy similar to that in previous reports, with no infusion-related reactions or increases in the frequency or severity of adverse events. Background: In some recently updated clinical guidelines, the fully humanized monoclonal antibody panitumumab, combined with irinotecan, has been recommended as an optional third-line chemotherapy for KRAS wild-type metastatic colorectal cancer (mCRC). The present prospective, multicenter phase II study evaluated the effectiveness and safety of short 15-minute panitumumab infusions. Patients and Methods: From January 2011 to December 2011, patients with KRAS wild-type mCRC were enrolled at 8 centers. The key eligibility criteria were age ! 20 years and resistance or intolerance to irinotecan, fluoropyrimidine, and oxaliplatin. All patients received 6 mg/kg of panitumumab and 150 mg/m 2 or the previous tolerated dose of irinotecan, biweekly, until disease progression or unacceptable toxicity. The initial panitumumab infusion was 60 minutes, followed by a 30-minute infusion and then 15-minute infusions. The primary endpoint was the confirmed response rate using Response Evaluation Criteria In Solid Tumors, version 1.0. The secondary endpoints were progression-free survival, overall survival, and toxicity. Department of Internal Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan Clinical Colorectal Cancer March 2018 -e83 survival were 5.8 months (95% CI, 3.3-8.4 months) and 13.6 months (95% CI, 10.8-16.5 months), respectively. The most frequent grade 3/4 toxicities were anorexia (12%), leukopenia (9%), and neutropenia (9%). Nine patients did not reach the 15-minute infusion, primarily because of disease progression. No infusion-related reactions were observed. Conclusion: The short 15-minute panitumumab infusion regimen was well tolerated, without compromising safety or efficacy in patients with KRAS wild-type, oxaliplatin-and irinotecan-refractory mCRC.
Introduction
Colorectal cancer (CRC) is the third-and fourth-leading cause of cancer-related morbidity and mortality worldwide. 1 In Japan, the number of CRC cases has rapidly increased in recent years, and it has become the second most common malignancy. Estimates have suggested that 104,700 new cases of CRC are diagnosed in Japan annually. 2 Although metastatic CRC (mCRC) is considered an incurable disease, cytotoxic agents and new molecularly targeted drugs have prolonged the survival times.
The monoclonal antibodies cetuximab and panitumumab, which both target epithelial growth factor receptor (EGFR), have been recommended as first-to third-line standard treatment of wild-type KRAS exon 2 mCRC. Recent data have suggested that patients with wild-type KRAS by extended analysis (exons 3 or 4 of KRAS or exons 2-4 of NRAS ) are likely to benefit from anti-EGFR therapy. [3] [4] [5] Panitumumab was developed subsequent to cetuximab; however, previous clinical trial data indicated that the 2 antibodies have almost equivalent efficacy. 6 However, several differences exist between these agents. Cetuximab is a chimeric monoclonal antibody, and panitumumab is a fully humanized monoclonal antibody. Therefore, infusion-related reactions are less frequent with panitumumab (0.5%) than with cetuximab (5%). 7, 8 In addition, the results of the BOND (randomized phase II trial in metastatic colorectal cancer that was refractory to treatment with irinotecan) trial have suggested that the combination of cetuximab and irinotecan has greater efficacy than cetuximab alone as third-line treatment. 9 A previous study demonstrated that the combination of panitumumab and irinotecan was effective in patients with KRAS wild-type, oxaliplatin-or irinotecanrefractory mCRC. 10 Thus, panitumumab and irinotecan chemotherapy has been recommended as an optional third-line chemotherapy in some updated clinical guidelines. 11, 12 Another study revealed that the 60-and 30-minute infusion regimens of panitumumab had similar safety and pharmacokinetic profiles, and no significant infusion-related reactions were observed. 13 Although a shorter, 15-minute infusion of panitumumab has the potential to enhance patient convenience, reported data on the feasibility of this regimen are not available. Therefore, a prospective, multicenter, phase II study was performed to determine the effectiveness and safety of 15-minute panitumumab infusions, using standard 60-minute infusions as a historical control (Short Infusion of Panitumumab [SHIP] trial).
Patients and Methods

Study Design and Eligibility Criteria
From January 2011 to December 2011, 43 patients who had received ! 1 cycle of treatment were enrolled from 8 Japanese institutions. The cutoff date for the collection of follow-up data was December 18, 2012.
The inclusion criteria were histologically confirmed adenocarcinoma, mucinous carcinoma, or signet ring-cell carcinoma; unresectable mCRC; KRAS wild-type; patient age 20 to 75 years; Eastern Cooperative Oncology Group performance status of 0, 1, or 2; expected survival ! 2 months after enrollment; ! 1 measurable lesion using the Response Evaluation Criteria In Solid Tumors (RECIST), version 1.0; resistance or intolerance to fluoropyrimidines, oxaliplatin, and irinotecan; and no previous anti-EGFR therapy. In addition, adequate bone marrow function (white blood cell count, ! 3000 cells/ mm 3 , platelet count ! 7.5 Â 10 4 /mm 3 , hemoglobin ! 8.0 g/dL), renal function (serum creatinine 1.5 mg/dL), hepatic function (bilirubin 1.5 times the upper limit of normal, aspartate aminotransferase and alanine aminotransferase 2.5 times the upper limit of normal); and treatment-free interval of ! 4 weeks since surgery, radiation, or chemotherapy were required.
The exclusion criteria were other active malignancies within the previous 5 years; a history of severe drug hypersensitivity; clinically significant infectious disease; severe complications, including obvious bowel obstruction, interstitial lung disease, pulmonary fibrosis, uncontrolled diabetes mellitus, and heart, renal, or hepatic failure; moderate to severe pleural effusion and/or ascites; symptomatic brain metastasis; blood transfusion required for gastrointestinal bleeding during the 14 days before enrollment; and any other cases deemed unsuitable for enrollment by the investigator.
The study was fully compliant with the Declaration of Helsinki. The institutional review board of each participating institution approved the study protocol. All the patients provided written informed consent before participation.
Treatment
All patients received biweekly chemotherapy consisting of panitumumab and irinotecan and antiemetic premedication with 5-HT 3 and dexamethasone. Panitumumab was administered at a dose of 6 mg/kg and irinotecan at a dose of either 150 mg/m 2 or the tolerated irinotecan dose during previous treatment. All chemotherapeutic and antiemetic agents were administered at the dose approved in Japan ( Figure 1 ). The initial panitumumab infusion was administered over 60 minutes, followed by a 30-minute infusion, and then 15-minute infusions, unless an infusion-related reaction occurred. Treatment was continued until disease progression or unacceptable toxicity. Preemptive topical adapalene and oral minocycline was administered to all patients with acne-like skin conditions, as previously described. 14 Panitumumab was stopped briefly in the case of grade 2
Phase II Study of 15-minute Panitumumab Infusion With Irinotecan infusion-related or hypersensitivity reactions. If the reaction resolved to grade 1 or less, the infusion was resumed at one half the previous infusion rate. If a patient experienced a grade ! 3 hypersensitivity reaction, chemotherapy was immediately discontinued, and intramuscular injections of epinephrine, an antihistamine drug, with or without intravenous steroids and oxygen, were given, in accordance with medical indications, and that protocol treatment was stopped and not resumed.
Assessment
The tumor response was assessed using RECIST, version 1.0, after every fourth administration until disease progression or withdrawal from the trial, corresponding to clinical practice. Responses were confirmed ! 28 days after the criteria for response had been first met. Tumor assessment was performed in accordance with each investigator's judgment. Toxicity was graded using the National Cancer Institute Common Toxicity Criteria, version 4.0.
Statistical Analysis
The primary outcome was assessed according to the intention-totreat principle. The primary endpoint was the confirmed objective response rate using RECIST, version 1.0. The key secondary endpoints were the feasibility of short 30-or 15-minute infusions of panitumumab, progression-free survival, overall survival, total objective response, and disease control rate. The total objective response rate was defined as the sum of the confirmed response rate and unconfirmed response rate. The unconfirmed response rate was defined as the percentage of patients without confirmation of the response ! 28 days after the response criteria had first been met. Stable disease was defined as assessment findings that did not meet the criteria for a total objective response or progressive disease during the treatment course. Progression-free survival was defined as the number of days from registration to disease progression or death from any cause, censored on the last day the patient was alive without evidence of progression. Overall survival was defined as the number of days from registration to death from any cause, censored on the last day the patient was alive. Progression-free survival and overall survival were analyzed using the Kaplan-Meier method, and the event rates are presented with the 95% confidence intervals (CIs) for each endpoint. The disease control rate was defined as the percentage of patients who achieved a complete response, partial response, and stable disease. The sample size of 40 subjects receiving panitumumab with irinotecan was determined from the expected and threshold response rates of 30% and 10%, respectively, as assumed from previous reports, 8, 9 and a and b errors of 0.05 and 0.1, respectively. All statistical analyses were conducted using SAS software, version 9.1.3 (SAS Institute, Cary, NC). The present trial is registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN no. 000004647).
Results
The baseline characteristics of the study population are listed in Table 1 . Of the 43 patients, the median age was 62 years (range, 32-75 years), and 58% were male. The Eastern Cooperative Oncology Group performance status was 0 or 1 for all patients, the primary location was the rectum in 53% of patients, and 67% of patients had previously been treated with bevacizumab.
After a median follow-up period of 16.8 months (range, 12.5-23.6 months), 10 patients continued treatment, and 19 and 13 patients had discontinued treatment because of disease 
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Clinical Colorectal Cancer March 2018 -e85 progression and adverse events, respectively ( Figure 2 ). With respect to the disease response, 16 patients had a partial response (8 responses were confirmed and 8 were unconfirmed), 13 patients had stable disease, 12 patients had disease progression, and 2 were not evaluable. The total response rate was 37.2% (95% CI, 23.0%-53.3%), and the confirmed response rate was 18.6% (95% CI, 8.4%-33.4%), with a disease control rate of 67.4% (95% CI, 51.5%-80.9%). Early tumor shrinkage, defined as > 30% reduction at the first evaluation, was observed in 35% of patients (Table 2 ). However, it was not possible to confirm a partial response in 7 of the patients with early shrinkage, mainly owing to inappropriate imaging studies during the follow-up period. The median interval from partial response to the next evaluation was 10.0 weeks (range, 8.1-19.3 weeks). The median progression-free survival was 5.8 months (95% CI, 3.3-8.4 months; Figure 3 ), and the median overall survival was 13.6 months (95% CI, 10.8-16.5 months; Figure 4 ). Of the 43 patients, 20 (47.6%) exhibited prominent tumor shrinkage during treatment ( Figure 5 ). The 60-minute infusion was administered to 43 patients for 62 doses, the 30-minute infusion to 40 patients for 55 doses, and the 15-minute infusion to 34 patients for 187 doses (Table 3) . During protocol treatment, 9 patients were unable to reach the 15-minute infusion for the following reasons: disease progression in 4, adverse events in 3 (diarrhea, constipation, and stomatitis), patient refusal by 1, and off-protocol treatment for 1 patient. No infusion-related reactions were experienced by any patient with any of the 3 infusion times. The most frequent hematologic toxicities were leukopenia (9%) and neutropenia (9%). Grade 3/4 nonhematologic toxicities included anorexia (12%), fatigue (7%), diarrhea (7%), rash acneiform (7%), stomatitis (5%), paronychia (5%), hyponatremia (2%), and hypomagnesemia (2%; Table 4 ). No patients were intolerant of the 15-minute infusion for any reason and required a return to an increased infusion duration.
Discussion
To the best of our knowledge, the present study is the first prospective study to describe the efficacy and feasibility of shorter 15-minute panitumumab infusions. With respect to efficacy, the present study has demonstrated that panitumumab with irinotecan is a promising treatment regimen for oxaliplatin-and/or irinotecan-refractory KRAS wild-type mCRC. Progression-free survival and overall survival were good, although the primary endpoint of a confirmed objective response rate was not met. In the GERCOR study (this study also prospectively analyzed the effect of panitumumab combined with irinotecan in patients refractory to standard chemotherapy), Andre et al 10 evaluated the combination of panitumumab and irinotecan in 65 patients with KRAS wild-type mCRC refractory to oxaliplatin, fluoropyrimidines, irinotecan, and bevacizumab. The objective response rate was 35.2%, and the disease control rate was 66.7%. The median progression-free and overall survival durations were 6.3 and 11.9 months, respectively. These data are similar to those in the present study. 10 Recently updated guidelines from both the National Comprehensive Cancer Network and the Japanese Society for Cancer of the Colon and Rectum have recommended the combination of panitumumab with irinotecan as third-line treatment of KRAS wild-type mCRC refractory to standard chemotherapy, including irinotecan. 11, 12 Because our results appear similar to those reported by Andre et al, 10 this regimen should also be considered for Japanese patients.
With respect to feasibility, the 15-minute panitumumab infusion did not induce infusion-related reactions in patients who were able to tolerate a 60-minute infusion, followed by a 30-minute infusion. The observed adverse events were within the acceptable range, and the treatment was performed safely. The 15-minute panitumumab infusion did not increase the incidence of adverse events compared with data from previous studies. Stephenson et al 13 evaluated the safety of an initial 60-minute panitumumab infusion followed by 30-minute infusions in 43 patients. No infusion-related reactions were reported; however, a conservative post hoc analysis indicated that 4 potentially infusion-related reactions occurred in 3 patients (7%). Nevertheless, panitumumab was not discontinued for any of the patients because of infusion-related reactions. Because panitumumab is a fully humanized monoclonal antibody, the frequency of infusion-related reactions is lower than that with the chimeric antibody cetuximab. The lower incidence of infusion and hypersensitivity reactions with panitumumab is also considered to be related to the absence of galactose-a-1,3 galactose on the Fab fragment. 15 In the case of the monoclonal antibody bevacizumab, which is not fully humanized, the safety of 10-minute infusions of bevacizumab (5 mg/kg) was investigated in 370 patients with CRC after administration of 2311 doses. Minor infusion-related reactions occurred in 6 patients; however, the results indicated that 10-minute infusions of bevacizumab were safe. 16 This led to the hypothesis that 15-minute infusions of panitumumab, a fully humanized monoclonal antibody, might also be safe and feasible. In the STEPP (skin toxicity evaluation protocol with panitumumab) trial, preemptive skin treatment reduced panitumumab-induced skin toxicity. 17 The incidence of grade 3/4 rash acneiform was 7% in our study, 4% in the STEPP trial, 17 and 32% in the GERCOR study. 10 This was also an effective pretreatment for acnelike skin care for patients administered the 15-minute panitumumab infusion. The present study had some limitations. In particular, a definitive conclusion regarding the safety of 15-minute panitumumab infusions could not be made, mainly because of the small study population and insufficient number of 15-minute infusion doses. To determine the frequency of rare adverse events (eg, 0.5%), it would be necessary to include a few hundred with > 300 cases to confirm safety. Because data from < 50 patients and 187 doses were available in the present study, additional information on the use of short panitumumab infusions in routine clinical practice must be accrued. Another factor is that the safety of a 15-minute infusion as the first dose was not evaluated. Because infusion-related reactions to panitumumab and cetuximab tend to occur during the first or second dose, a 60-minute infusion followed by a 30-minute infusion might enable desensitization and decrease the risk of infusion-related reactions during subsequent 15-minute infusions. However, information on desensitization is not available owing to the rarity of panitumumab-related infusion reactions. Desensitization to cetuximab has been successful, and a protocol is available. 18 In the present study, the primary endpoint of an objective confirmed response rate was inferior to that in a previous study. 10 However, the proportion of patients with early tumor shrinkage and the total response rate were favorable. The discrepancy between the confirmed response rate and the total response rate was probably caused by the delayed confirmation of responses because the median interval from a partial response to the next evaluation was 10 weeks (range, w8-20 weeks).
Conclusions
Panitumumab with irinotecan was effective in patients with KRAS wild-type oxaliplatin-or irinotecan-refractory mCRC. Furthermore, no infusion-related reactions or obvious increases in the frequency and severity of adverse events occurred after administration of 15-minute panitumumab infusions from the third dose among patients able to tolerate a 60-minute infusion, followed by a 30-minute infusion. These findings suggest that 15-minute panitumumab infusions are both efficacious and feasible. Also, the shorter infusion time increases the convenience of outpatient chemotherapy.
Clinical Practice Points
Our study has demonstrated the efficacy and feasibility of short 30-and/or 15-minute panitumumab infusions. There were no infusion-related reactions with 60-, 30-, or 15-minute panitumumab infusions and no increase in the frequency and severity of adverse events. Survival data after the shorter 15-minute panitumumab infusion with irinotecan in patients with KRAS wild-type, oxaliplatin-or irinotecan-refractory mCRC were similar to those in previous reports. 
